Influenza

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

NCT01113580 | PHASE 4 | INTERVENTIONAL

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.

1 Sites

120 Participants

Recruiting

18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Chiltern (Early Phase) Limited

Dundee,Angus and Dundee,United Kingdom,DD19SY

Study Eligibility Criteria

Inclusion Criteria

* Male or female aged 18 years and older at the time of the first study vaccination.

Exclusion Criteria

* Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.
* Clinical signs of an active infection
* Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry
* Females who are pregnant or lactating

Additional Studies

Additional studies can be found at ClinicalTrials.gov